Millennium Management’s Gyre Therapeutics GYRE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-35,751
| Closed | -$267K | – | 6188 |
|
|
2025
Q3 | $267K | Buy |
+35,751
| New | +$271K | ﹤0.01% | 5393 |
|
|
2024
Q2 | – | Sell |
-60,319
| Closed | -$1.05M | – | 6146 |
|
|
2024
Q1 | $1.05M | Buy |
+60,319
| New | +$1.09M | ﹤0.01% | 4250 |
|
|
2023
Q2 | – | Sell |
-18,154
| Closed | -$56K | – | 6339 |
|
|
2023
Q1 | $56K | Sell |
18,154
-7,849
| -30% | -$29.8K | ﹤0.01% | 5594 |
|
|
2022
Q4 | $103K | Sell |
26,003
-93,293
| -78% | -$381K | ﹤0.01% | 5574 |
|
|
2022
Q3 | $451K | Buy |
119,296
+74,318
| +165% | +$944K | ﹤0.01% | 5046 |
|
|
2022
Q2 | $600K | Sell |
44,978
-40,062
| -47% | -$266K | ﹤0.01% | 4809 |
|
|
2022
Q1 | $421K | Sell |
85,040
-36,192
| -30% | -$179K | ﹤0.01% | 5251 |
|
|
2021
Q4 | $831K | Buy |
121,232
+31,735
| +35% | +$543K | ﹤0.01% | 4577 |
|
|
2021
Q3 | $2.76M | Sell |
89,497
-15,536
| -15% | -$511K | ﹤0.01% | 3540 |
|
|
2021
Q2 | $3.41M | Buy |
105,033
+33,130
| +46% | +$1.14M | ﹤0.01% | 3284 |
|
|
2021
Q1 | $2.72M | Sell |
71,903
-19,288
| -21% | -$882K | ﹤0.01% | 3232 |
|
|
2020
Q4 | $4.32M | Sell |
91,191
-35,467
| -28% | -$1.54M | ﹤0.01% | 2581 |
|
|
2020
Q3 | $4.08K | Sell |
126,658
-25,787
| -17% | -$1.01M | 0.01% | 2020 |
|
|
2020
Q2 | $6.71M | Buy |
152,445
+6,067
| +4% | +$285K | 0.01% | 1520 |
|
|
2020
Q1 | $4.8M | Buy |
146,378
+50,729
| +53% | +$2.33M | 0.01% | 1358 |
|
|
2019
Q4 | $4.88M | Buy |
95,649
+1,870
| +2% | +$78.4K | 0.01% | 1963 |
|
|
2019
Q3 | $3.45M | Buy |
93,779
+17,871
| +24% | +$963K | 0.01% | 2076 |
|
|
2019
Q2 | $4.2M | Buy |
75,908
+529
| +0.7% | +$33.1K | 0.01% | 1917 |
|
|
2019
Q1 | $4.58M | Buy |
75,379
+36,334
| +93% | +$2.33M | 0.01% | 1832 |
|
|
2018
Q4 | $2.31M | Sell |
39,045
-7,333
| -16% | -$541K | ﹤0.01% | 2110 |
|
|
2018
Q3 | $3.75M | Buy |
46,378
+17,858
| +63% | +$1.42M | ﹤0.01% | 2010 |
|
|
2018
Q2 | $2.5M | Buy |
28,520
+20,147
| +241% | +$3.53M | ﹤0.01% | 2251 |
|
|
2018
Q1 | $1.62M | Buy |
+8,373
| New | +$1.56M | ﹤0.01% | 2437 |
|
|
2017
Q1 | – | Sell |
-145
| Closed | -$11K | – | 3622 |
|
|
2016
Q4 | $11K | Buy |
+145
| New | +$13K | ﹤0.01% | 3285 |
|
|
2015
Q1 | – | Sell |
-25
| Closed | -$52K | – | 3783 |
|
|
2014
Q4 | $52K | Buy |
25
+3
| +14% | +$5.78K | ﹤0.01% | 3826 |
|
|
2014
Q3 | $44K | Sell |
22
-66
| -75% | -$163K | ﹤0.01% | 3604 |
|
|
2014
Q2 | $311K | Buy |
88
+59
| +203% | +$193K | ﹤0.01% | 2856 |
|
|
2014
Q1 | $110K | Sell |
29
-268
| -90% | -$992K | ﹤0.01% | 3283 |
|
|
2013
Q4 | $970K | Sell |
297
-297
| -50% | -$1.17M | ﹤0.01% | 2321 |
|
|
2013
Q3 | $2.48M | Buy |
594
+167
| +39% | +$672K | 0.01% | 1549 |
|
|
2013
Q2 | $1.44M | Buy |
+427
| New | +$1.62M | ﹤0.01% | 1776 |
|
Other funds holding GYRE
SS
Millennium Management's GYRE Position: Q4 2025 in Review
Millennium Management sold out of Gyre Therapeutics (GYRE) in Q4 2025, closing a stake of 35,751 shares — an estimated $267K sold.
Millennium Management first reported a position in GYRE in Q2 2013 and held it in 31 quarters. The position peaked at $6.71M in Q2 2020. 44 funds tracked by Wall St. Rank hold GYRE as of Q4 2025.
- Millennium Management reported no remaining Gyre Therapeutics position as of Q4 2025 after selling out during the quarter.
- Millennium Management sold 35,751 Gyre Therapeutics shares in Q4 2025, an estimated $267K.
- Millennium Management first reported a position in Gyre Therapeutics in Q2 2013 and held it in 31 quarters.
- Millennium Management's Gyre Therapeutics position peaked at $6.71M in Q2 2020.
- 44 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q4 2025.
Based on Millennium Management's 13F filing for Q4 2025, filed 17 Feb 2026.